GILD vs QGEN
Gilead Sciences, Inc. and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GILD | QGEN |
|---|---|---|
| Revenue | $29.4B | $2.1B |
| Net income | $8.5B | $424.9M |
| Gross margin | 78.8% | 62.2% |
| Net margin | 28.9% | 20.3% |
| Return on equity | 40.5% | 11.6% |
| Diluted EPS | $6.78 | $1.94 |
| Dividend / share | $3.16 | $0.25 |
| Payout ratio | 47.0% | 12.8% |
| Free cash flow | $9.5B | $453.3M |
| Equity | $22.7B | $3.8B |
| Net debt / equity | 0.77× | 0.22× |
| Current ratio | 1.55× | 3.90× |
| Revenue CAGR 5y | 3.6% | 2.2% |
| Profit CAGR 5y | 133.3% | 3.4% |
GILD bills 14.1× the revenue of QGEN, and keeps more of each dollar of revenue as profit (28.9% against 20.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | GILD | QGEN |
|---|---|---|
| FY2025 | $29.4B | $2.1B |
| FY2024 | $28.8B | $2.0B |
| FY2023 | $27.1B | $2.0B |
| FY2022 | $27.3B | $2.1B |
| FY2021 | $27.3B | $2.3B |
| FY2020 | $24.7B | $1.9B |
| FY2019 | $22.4B | $1.5B |
| FY2018 | $22.1B | $1.5B |
| FY2017 | $26.1B | $1.4B |
| FY2016 | $30.4B | $1.3B |
Net income by year
Bottom line
| Fiscal year | GILD | QGEN |
|---|---|---|
| FY2025 | $8.5B | $424.9M |
| FY2024 | $480.0M | $83.6M |
| FY2023 | $5.7B | $341.3M |
| FY2022 | $4.6B | $423.2M |
| FY2021 | $6.2B | $512.6M |
| FY2020 | $123.0M | $359.2M |
| FY2019 | $5.4B | $-41.5M |
| FY2018 | $5.5B | $190.4M |
| FY2017 | $4.6B | $40.4M |
| FY2016 | $13.5B | $80.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry